At Future Fields, we know how important your supply chain is. You need cost-effective recombinant proteins that perform to the highest standards. You have production goals that you need to consistently hit without breaking your budget. While there are many inputs that contribute to the success of your manufacturing processes, one input you can always count on are Future Fields products.
Produced with our EntoEngine platform, Future Fields’ recombinant proteins provide consistent performance across multiple metrics - so you can get the most out of your cell cultures every time.
Cell Morphology: Observing the morphology of cells in culture provides the first indicator of cell health. For myoblasts, like C2C12 cells, cell morphology can also indicate the stage of myogenesis that the cells are in. Myogenesis is the formation of muscle tissue involving the steps of cell proliferation, cell differentiation, formation of myotubes, and cellular fusion.
During proliferation of healthy C2C12 myoblasts, we expect to see cytoplasmic radial branching extending in many directions and a single nucleus. Myoblasts cultured in media containing Future Fields’ purified Bovine FGF2 or Ento-F FGF2 and passaged before reaching confluency remain in a proliferative state (Figure 1.).
Figure 1. Serum-free adapted C2C12 cells were grown for 96 hours in medium containing a competitor source of human FGF2, Future Fields’ purified bovine FGF2 or Ento-F FGF2.
Metabolic Activity: The overall health of cells in culture can be determined by the cellular metabolic activity, an indicator of cell viability and proliferation. We use this assay to measure the effect that different FGF2 growth factor sources in the media have on cellular health.
Myoblasts grown in Future Fields’ purified Bovine FGF2 or Ento-F FGF2 reliably show excellent viability compared to competitors. Even at low seeding densities, cells grown in media with Ento-F FGF2 robustly recover and thrive, showing much greater metabolic activity than cultures grown with other sources of FGF2 (Figure 2.).
Figure 2. Serum-free adapted C2C12 cells were seeded at 938 cells/cm² and treated for 96 hours with medium containing competitor sources of human FGF2, Future Fields’ purified bovine FGF2 or Ento-F FGF2. Metabolic activity was measured by a resazurin cell viability assay. The optical density measurements were normalized to the E. coli competitor values.
Population Doubling: The population doubling time or growth rate of a cell culture is the time required for a cell population to double its size, reaching exponential growth. Many factors contribute to growth rate such as cell density, availability of nutrients and presence of growth factors. FGF2 in particular promotes cellular proliferation in culture.
We validate the bioactivity of our growth factors with a cell proliferation assay using C2C12 myoblasts. Future Fields’ purified Bovine FGF2 and Ento-F FGF2 consistently show significantly superior population doubling compared to competitors and a commercially available complete serum-free medium (Figure 3.).
Figure 3. Serum-free adapted C2C12 cells were seeded at 6000 cells/cm² and treated for 72 hours with medium containing competitor sources of human FGF2, Future Fields’ purified bovine FGF2 or Ento-F FGF2. The experiment was blinded and population doubling was measured by cell counting. Results are relative to a commercially available complete serum-free media. Biological replicates: Bovine FGF2 n=47, Ento-F FGF2 n=106, E. coli competitor n=53, Plant competitor n=14. The lesser statistical significance of the comparisons to the Plant competitor are a reflection of the lower number of replicates performed thus far.
Batch Consistency: The quality and consistency of all of our Future Fields’ products is highly important to confirm regulatory compliance, but more vitally, to ensure that our customers can rely on our products with every purchase. Batch-to-batch comparisons of our Ento-F FGF2 are regularly re-tested within the same assay to confirm performance consistency (Figure 4.).
Figure 4. Serum-free adapted C2C12 cells were seeded at 6000 cells/cm² and treated for 72 hours with medium containing a competitor source of human FGF2 or Future Fields’ Ento-F FGF2. The experiment was blinded and population doubling was measured by cell counting.
We have three products available on the market today:
Ento-F (bovine): Future Fields Ento-F FGF2 is an Enriched Growth Media Supplement as an aqueous solution that can directly replace FGF2 needs in cell culture. Produced with the EntoEngine™ recombinant protein platform, the supplement comes in a 1000X concentrate, containing enough recombinant bovine FGF2 to sustain cell culture in two and three dimensions with cross species performance equivalent or better than expensive alternatives. Ento-F is the most cost effective and sustainable option for cell culture FGF2 needs on the market today.
FGF2 (bovine): Future Fields Recombinant Bovine FGF2 (> 95 % purity) produced with the EntoEngine™ recombinant protein platform. Fulfills the needs of FGF2 requirements in cell culture across a variety of land-dwelling and aquatic species.
Ento-Tf (bovine): Transferrin Enriched Growth Media Supplement. 1000X concentrate recombinant bovine Transferrin enriched growth media supplement produced with the EntoEngine™ recombinant protein platform.
Don’t see what you need? We have 11 additional products in our pipeline: insulin, LIF, IL-6, VEGF, EGF, NRG1, TGF𝛃3, TGF𝛃1, IGF-1, prolactin, and albumin.